Abbott Laboratories (NYSE: ABT) reported higher sales and adjusted earnings for the third quarter of fiscal 2025. The healthcare company also reaffirmed its full-year 2025 guidance.
Total sales increased 6.9% year-over-year to $11.37 billion in the third quarter, which is broadly in line with analysts’ estimates. Organic sales grew 5.5%, or 7.5% excluding COVID-19 testing-related sales.
Adjusted earnings rose to $1.30 per share in Q3 from $1.21 per share in the year-ago quarter, matching market watchers’ expectations. Unadjusted net income was $1.64 billion or $0.94 per share in the third quarter, unchanged from the profit reported in Q3 2024.
The Abbott leadership reaffirmed the midpoint of its previously provided full-year 2025 adjusted earnings per share guidance, narrowing the range to $5.12 to $5.18.
“Our third-quarter results demonstrate our ability to deliver consistent, high-quality performance. Our differentiated product pipeline continues to power our performance and positions Abbott to deliver durable long-term value to our shareholders,” said Robert Ford, chief executive officer of Abbott.
